Conference Proceedings

Study of the dosimetry, safety, and potential benefit of 177Lu-PSMA-617 radionuclide therapy prior to radical prostatectomy in men with high-risk localized prostate cancer (LuTectomy study).

Omar Alghazo, Renu Eapen, Nattakorn Dhiantravan, John A Violet, Price Jackson, Mark Scalzo, Simon P Keam, Catherine Mitchell, Paul J Neeson, Shahneen Kaur Sandhu, Scott Williams, Daniel Moon, Nathan Lawrentschuk, Arun Azad, Michael S Hofman, Declan G Murphy

JOURNAL OF CLINICAL ONCOLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2021

Abstract

TPS264 Background: High-risk localised prostate cancer (HRCaP) is treated by radical prostatectomy (RP) or radiotherapy. Despite curative intent, a significant number of men will progress with metastatic disease or local recurrence. Lutetium-177 radiolabelled to the small molecule PSMA-617 targeting prostate-specific membrane antigen (Lu-PSMA) has proven efficacious in men with metastatic castration-resistant prostate cancer who have progressed after standard-of-care. The LuTectomy trial evaluates whether administration of Lu-PSMA before radical prostatectomy in men with HRCaP will deliver high doses of radiation to the prostate and involved lymph nodes. It also aims to assess the feasibili..

View full abstract

Grants

Funding Acknowledgements

Movember and Medical Research Future Fund (MRFF), Endocyte Inc., a Novartis Company, E.J. Whitten Foundation.